Open an account

Regeneron Pharmaceuticals

REGN · NASDAQ

$807.48+$25.44 (+3.25%)TodayMarket closed ·
Prev close $782.04

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.

Employees
15,410
Headquarters
Tarrytown, New York
Listed
Apr 2, 1991
Sector
Health Care
Industry
Biotechnology
Website
regeneron.com

REGN key statistics

Market cap
80.51B
Price-earnings ratio
19.32
Dividend yield
0.46%
Average volume
676.26K
Volume
399.78K
Open price
$793.85
High today
$807.86
Low today
$789.69
52 Week high
$859.34
52 Week low
$564.00

Regeneron Pharmaceuticals (REGN) at a glance

As of Oct 20, 2026, Regeneron Pharmaceuticals (REGN) shares are priced at $807.48, giving the company a market cap of 80.51B, a price-to-earnings ratio of 19.32 and a dividend yield of 0.46%.

Today the stock has traded between $789.69 and $807.86. The current price is 2.3% above the day's low and 0.0% below its high.

Volume so far is 399.78K shares, below the average of 676.26K shares a day.

Over the past year Regeneron Pharmaceuticals has ranged from $564.00 to $859.34, and now sits 82% of the way up that range.

Regeneron Pharmaceuticals met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $14.29 per share against an estimate of $10.47.

The average analyst price target is $863.09, 6.9% above the current price, from 28 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

71%of 28 analyst ratings say Buy
  • Buy71.4%
  • Hold25.0%
  • Sell3.6%
Price target · 32 analystsAvg $863.09
Low
$742.45
Now
$807.48
High
$1,081.50

REGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 18.0% on average.

  1. Q3 FY24: reported $12.46 per share against an estimate of $11.93
  2. Q4 FY24: reported $12.07 per share against an estimate of $11.50
  3. Q1 FY25: reported $8.22 per share against an estimate of $9.00
  4. Q2 FY25: reported $12.89 per share against an estimate of $8.61
  5. Q3 FY25: reported $11.83 per share against an estimate of $9.78
  6. Q4 FY25: reported $11.44 per share against an estimate of $10.83
  7. Q1 FY26: reported $9.47 per share against an estimate of $9.12
  8. Q2 FY26: reported $14.29 per share against an estimate of $10.47

REGN news

  • Vandana Singh

    Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth

  • Piero Cingari

    Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average

  • Vandana Singh

    Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data

  • Vandana Singh

    Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion

  • Press releaseGlobe Newswire

    Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

  • Press releaseGlobe Newswire

    Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

  • Vandana Singh

    Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug

  • Vandana Singh

    Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine

Similar companies

Companies in the same industry as Regeneron Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.